DESTINY (Trudy)

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST

CANCER WHO HAVE RESIDUAL INVASIVE DISEASE

IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY

PI Dr. med. M. Aydogdu

Multizentrische, prospektiv randomisierte Phase III Studie zum Vergleich einer antineoplastischen Therapie allein versus einer antineoplastischen Therapie plus Lapatinib bei Pat. mit initial HER2-negativem metastasiertem Brustkrebs und HER2-positiven zirkulierenden Tumorzellen

Universitätsklinikum Ulm - PI Dr. med. M. Aydogdu

Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin (trastuzumab) and Perjeta (pertuzumab) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer

Universitätsklinikum Ulm - PI Dr. T. Hempel

Phase III Studie zur Evaluation von Palbociclib ein Hemmer der Cyclin-Kinase 4/6 bei Pat. mit HR+/HER2-normalem primärem Brustkrebs mit hohem Rückfallrisiko nach neoadjuvanter Chemotherapie

GBG Forschung GmbH - PI Dr. med. M. Aydogdu

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk

HER2negative primary breast cancer who have completed defintive local treatment and neoadjuvant or adjuvant chemotherapy

Astra Zeneca - PI Dr. med. M. Aydogdu

Breast cancer in Pregnancy Prospektive und Retrospektive Registerstudie der German Breast Group (GBG) zur Diagnostik und Therapie des Mammaca. in der Schwangerschaft

GBG Forschung GmbH - PI Dr. med. M. Aydogdu

Pelvic and Para-aortic Lymphadenectomy in Patients with Stage I or II Endometrial Cancer with High Risk of Recurrence. A Multicenter, Prospective Randomized Controlled Trial

KKS Marburg - PI Dr. med. M. Aydogdu